Establishment and Characterization of Gastric Cancer PDC Lines

Gastric cancer PDC lines JSC15-3 and JSC18-1 were established in JFCR from 2015 to 2018 under approval from the Institutional Review Board of JFCR, with written informed consent from patients in accordance with Declaration of Helsinki, as described previously (20 (link)). JSC15-3 cells were cultured in ACL4/F12 (1:1) medium (Nacalai Tesque) supplemented with 5% heat-inactivated FBS and 100 µg/mL kanamycin (Meiji Seika Pharma). JSC18-1 cells were cultured in ACL4/RPMI (1:1) medium supplemented with 5% heat-inactivated FBS and 100 µg/mL kanamycin. Cells were routinely tested for Mycoplasma contamination by PCR using the primers 5′-CACCATCTGTCACTCTGTTAACC-3′ and 5′-GGAGCAAACAGGATTAGATACCC-3′. Mycoplasma testing was also performed in 2021 by ICLAS monitoring center, Central Institute for Experimental Animals (Kanagawa, Japan).